Management of Patients with Oral Candidiasis

Camilla Kragelund; Jesper Reibel; Anne Marie Lynge Pedersen

doi:10.1007/978-3-319-25091-5_13

Management of Patients with Oral Candidiasis

Camilla Kragelund, Jesper Reibel, Anne Marie Lynge Pedersen

Sektion 01

1 Citationer (Scopus)

Abstract

Oral candidal infections are medically treated with antifungal agents. In the fungal cell membrane, steroid ergosterol is the target of the antifungals on the market, but similarity with the human cell membrane may cause host toxicity and unintended reactions. Management of oral candidiasis depends on several factors, some are host-sensitive parameters, systemic diseases and drug exposure, and others are infection-sensitive parameters, duration of the infection and the virulence of the infecting Candida species. Treatment failure might be associated with acquired or native azole resistance in particular in patients with recurrent oral candidiasis. This risk can be reduced if different types of antifungal drugs are used over time or are combined. This chapter focuses on antifungal treatment of the medically compromised patient with oral candidiasis by highlighting the advantages and disadvantages of different antifungals.

Originalsprog	Engelsk
Titel	Oral Infections and General Health : From Molecule to Chairside
Redaktører	Anne Marie Lynge Pedersen
Antal sider	7
Udgivelsessted	Heidelberg
Forlag	Springer
Publikationsdato	1 jan. 2015
Udgave	1
Sider	137-144
Kapitel	13
ISBN (Trykt)	978-3-319-25089-2
ISBN (Elektronisk)	978-3-319-25091-5
DOI	https://doi.org/10.1007/978-3-319-25091-5_13
Status	Udgivet - 1 jan. 2015

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1007/978-3-319-25091-5_13

http://link.springer.com/book/10.1007%2F978-3-319-25091-5

Citationsformater

@inbook{41a5a0b88927467582dbbe822183a58f,

title = "Management of Patients with Oral Candidiasis",

abstract = "Oral candidal infections are medically treated with antifungal agents. In the fungal cell membrane, steroid ergosterol is the target of the antifungals on the market, but similarity with the human cell membrane may cause host toxicity and unintended reactions. Management of oral candidiasis depends on several factors, some are host-sensitive parameters, systemic diseases and drug exposure, and others are infection-sensitive parameters, duration of the infection and the virulence of the infecting Candida species. Treatment failure might be associated with acquired or native azole resistance in particular in patients with recurrent oral candidiasis. This risk can be reduced if different types of antifungal drugs are used over time or are combined. This chapter focuses on antifungal treatment of the medically compromised patient with oral candidiasis by highlighting the advantages and disadvantages of different antifungals.",

author = "Camilla Kragelund and Jesper Reibel and Pedersen, {Anne Marie Lynge}",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-3-319-25091-5_13",

language = "English",

isbn = "978-3-319-25089-2",

pages = "137--144",

editor = "Pedersen, {Anne Marie Lynge}",

booktitle = "Oral Infections and General Health",

publisher = "Springer",

edition = "1",

}

TY - CHAP

T1 - Management of Patients with Oral Candidiasis

AU - Kragelund, Camilla

AU - Reibel, Jesper

AU - Pedersen, Anne Marie Lynge

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Oral candidal infections are medically treated with antifungal agents. In the fungal cell membrane, steroid ergosterol is the target of the antifungals on the market, but similarity with the human cell membrane may cause host toxicity and unintended reactions. Management of oral candidiasis depends on several factors, some are host-sensitive parameters, systemic diseases and drug exposure, and others are infection-sensitive parameters, duration of the infection and the virulence of the infecting Candida species. Treatment failure might be associated with acquired or native azole resistance in particular in patients with recurrent oral candidiasis. This risk can be reduced if different types of antifungal drugs are used over time or are combined. This chapter focuses on antifungal treatment of the medically compromised patient with oral candidiasis by highlighting the advantages and disadvantages of different antifungals.

AB - Oral candidal infections are medically treated with antifungal agents. In the fungal cell membrane, steroid ergosterol is the target of the antifungals on the market, but similarity with the human cell membrane may cause host toxicity and unintended reactions. Management of oral candidiasis depends on several factors, some are host-sensitive parameters, systemic diseases and drug exposure, and others are infection-sensitive parameters, duration of the infection and the virulence of the infecting Candida species. Treatment failure might be associated with acquired or native azole resistance in particular in patients with recurrent oral candidiasis. This risk can be reduced if different types of antifungal drugs are used over time or are combined. This chapter focuses on antifungal treatment of the medically compromised patient with oral candidiasis by highlighting the advantages and disadvantages of different antifungals.

U2 - 10.1007/978-3-319-25091-5_13

DO - 10.1007/978-3-319-25091-5_13

M3 - Book chapter

SN - 978-3-319-25089-2

SP - 137

EP - 144

BT - Oral Infections and General Health

A2 - Pedersen, Anne Marie Lynge

PB - Springer

CY - Heidelberg

ER -

Management of Patients with Oral Candidiasis

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater